Upstream Bio, Inc. (UPB)
5.34
+0.03
(+0.56%)
USD |
NASDAQ |
Sep 18, 16:00
5.35
+0.01
(+0.19%)
After-Hours: 20:00
Upstream Bio Enterprise Value : 32.12M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 32.12M |
| September 17, 2026 | 30.48M |
| September 16, 2026 | 31.58M |
| September 15, 2026 | 39.79M |
| September 14, 2026 | 57.87M |
| September 11, 2026 | 53.48M |
| September 10, 2026 | 54.58M |
| September 09, 2026 | 66.08M |
| September 08, 2026 | 78.68M |
| September 04, 2026 | 68.82M |
| September 03, 2026 | 72.65M |
| September 02, 2026 | 94.56M |
| September 01, 2026 | 98.40M |
| August 31, 2026 | 102.23M |
| August 28, 2026 | 106.06M |
| August 27, 2026 | 111.54M |
| August 26, 2026 | 130.16M |
| August 25, 2026 | 132.90M |
| August 24, 2026 | 101.68M |
| August 21, 2026 | 121.40M |
| August 20, 2026 | 114.83M |
| August 19, 2026 | 151.25M |
| August 18, 2026 | 114.83M |
| August 17, 2026 | 130.71M |
| August 14, 2026 | 126.88M |
| Date | Value |
|---|---|
| August 13, 2026 | 118.11M |
| August 12, 2026 | 118.11M |
| August 11, 2026 | 127.97M |
| August 10, 2026 | 147.14M |
| August 07, 2026 | 136.74M |
| August 06, 2026 | 115.92M |
| August 05, 2026 | 108.80M |
| August 04, 2026 | 111.54M |
| August 03, 2026 | 91.28M |
| July 31, 2026 | 85.25M |
| July 30, 2026 | 99.49M |
| July 29, 2026 | 90.73M |
| July 28, 2026 | 90.18M |
| July 27, 2026 | 90.18M |
| July 24, 2026 | 90.73M |
| July 23, 2026 | 90.18M |
| July 22, 2026 | 100.59M |
| July 21, 2026 | 121.95M |
| July 20, 2026 | 121.95M |
| July 17, 2026 | 123.59M |
| July 16, 2026 | 135.64M |
| July 15, 2026 | 137.83M |
| July 14, 2026 | 130.71M |
| July 13, 2026 | 138.38M |
| July 10, 2026 | 152.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sutro Biopharma, Inc. | 339.78M |
| Compass Therapeutics, Inc. | 171.92M |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.70M |
| Revenue (Quarterly) | 0.773M |
| Total Expenses (Quarterly) | 40.48M |
| EPS Diluted (Quarterly) | -0.7276 |
| Gross Profit Margin (Quarterly) | 93.53% |
| Profit Margin (Quarterly) | -5.14K% |
| Earnings Yield | -54.05% |
| Normalized Earnings Yield | -53.99 |